| Bioactivity | ALK-IN-29 (compound 4c) has a certain inhibitory effect on tyrosine protein kinases ALK, CDK2/CyclinE1 and FAK, among which the strongest inhibitory effect on ALK kinase is 40.63% at a concentration of 10 μM. ALK-IN-29 can be used for anti-cancer research[1]. |
| CAS | 2244986-40-9 |
| Formula | C26H26BrN5O |
| Molar Mass | 504.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhou L, et al. Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader. J Med Chem. 2024 Oct 24;67(20):18247-18264. |
CDK12/13 ligand 1
CAS: 2244986-40-9 F: C26H26BrN5O W: 504.42
ALK-IN-29 (compound 4c) has a certain inhibitory effect on tyrosine protein kinases ALK, CDK2/CyclinE1 and FAK, among wh
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.